List of Bioinformatics Companies in Israel - 17

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

Bsense Bio Therapeutics is developing small molecules for the treatment of sensory hyperexcitability related disorders. Bsense is pioneering a novel approach targeting multiple hyperexcitability related mechanisms using a single compound, to achieve greater efficacy and safety. Sensory neuron Hyperexcitability refers to a multitude of indications such as Pain, Pruritus, Tinnitus and seizure, in which sensory neurons are excessively active leading to dire clinical and quality of life ramifications for patients. These indications are considered as significant unmet medical needs representing a major healthcare burden. Bsense Bio's approach is based on the targeting of two cation channels, a ligand-gated cation channel and a voltage-gated potassium channel, respectively, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in the modulation of neuronal excitability. The company has generated preclinical proof-of-concept in chronic pain and has recently been generating data in additional hyperexcitability indications in the space of Pruritis and Tinnitus (some of which with Orphan disease designation). The company is financed by Takeda Ventures Inc., OrbiMed Israel Partners, and Johnson & Johnson Innovation (JJDC), RMGP and the Israel Innovation Authority (IIA). Bsense was founded in September 2018 at the FutuRx biotech incubator based on technology that originated from Prof. Bernard Attali and Dr. Asher Peretz work from the Tel Aviv University.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

An internationally-recognized and multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computational sciences, plant science, precision agriculture and environmental sciences as well as food, nutrition and health.

Minovia Therapeutics is a clinical-stage international biotechnology company, established in hopes to bring life changing therapies to patients with Mitochondrial diseases, as fast as responsible. Following compassionate use cases performed in Sheba Medical hospital in Israel, using our proprietary Mitochondrial Augmentation Therapy, Minovia is now conducting the first of its kind clinical trial for Pearson syndrome, an ultra-rare pediatric disease.

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression. Proud winner of the "Coller Startup Competition" for Edition 2023.

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom's disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being. Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

SKIP Therapeutics develops RNA-based therapies for rare genetic disorders and common diseases – utilizing a proprietary computational discovery engine to optimize target selection and therapeutic design. We employ sequence-based molecules, called Antisense Oligonucleotides (ASO), to restore function of mutated genes in rare genetic disorders or to modify functionality of key genes in major disease pathways. Convergence of SKIP’s novel computational discovery engine alongside strong experimental capabilities form a unique venture in the landscape of RNA-based therapies. Thousands of rare genetic disorders affect millions of people worldwide, however the small number of patients for each disease, further segregated by patient-specific mutations, has hindered development of dedicated treatments. Recent advancements in RNA-therapeutics offer an expanded molecular toolkit that can be deployed rapidly and at low costs to restore protein function of mutated genes. Identifying sub patient-populations that could potentially be suitable for treatment with RNA-based therapeutics and matching molecular treatment-strategies across the vast landscape of known disease-causing mutations could be assisted by computational methods. To facilitate development of dedicated treatments, Skip Therapeutics has developed a bioinformatic pipeline that analyzes disease-causing mutations and recognizes the best molecular strategy (if any) to restore protein function, using splice modulating antisense oligonucleotides (ASOs). Analyzing mutation data at scale, enables identification of treatable patient cohorts and optimizes target selection. Top candidates from the computational analyses are experimentally validated and pursued for therapeutic development.

Ukko is improving the lives of millions that suffer from food allergies and disorders. We are using cutting edge technologies in immunology, computational biology, and plant science to develop a new approach. We have offices in Tel Aviv, Israel and Palo Alto, California.